论文部分内容阅读
目的探讨卵巢上皮性肿瘤中B7-H4和葡萄糖转运体蛋白1(GLUT-1)的表达及其与肿瘤生物学行为的关系和意义。方法选取2008年1月-2014年1月在该院行手术切除的190例正常卵巢组织及上皮性卵巢肿瘤组织标本,其中正常卵巢组织30例,良性肿瘤组织40例,交界性肿瘤组织40例,上皮性卵巢恶性肿瘤组织80例。采用免疫组化法检测各类卵巢组织标本中B7-H4和GLUT-1的表达情况,研究两者的表达与临床病理特征的关系。结果在上皮性卵巢恶性肿瘤组织中B7-H4和GLUT-1的表达显著高于正常卵巢组织、卵巢良性组织及交界性肿瘤组织,差异均有统计学意义(P<0.05)。B7-H4和GLUT-1在低分化卵巢恶性肿瘤组织中的阳性表达率均明显高于高、中分化(P<0.05),Ⅲ~Ⅳ期卵巢恶性肿瘤组织中的阳性表达率也明显高于卵巢恶性肿瘤Ⅰ~Ⅱ期(P<0.05),而GLUT-1表达阳性者淋巴结转移率较高(P<0.05);B7-H4在卵巢浆液性恶性肿瘤中的阳性表达率高于黏液性恶性肿瘤(P<0.05),且均与淋巴结转移及年龄等无关。结论 B7-H4及GLUT-1在上皮性卵巢恶性肿瘤中的表达升高,为卵巢癌的诊断及治疗提供新的理论依据。
Objective To investigate the expression and significance of B7-H4 and GLUT-1 in epithelial ovarian tumors and its biological behavior. Methods From January 2008 to January 2014, 190 cases of normal ovarian tissue and epithelial ovarian tumor specimens surgically removed from the hospital were selected, including 30 normal ovarian tissues, 40 benign tumor tissues, 40 borderline tumor tissues , Epithelial ovarian cancer tissue 80 cases. Immunohistochemistry was used to detect the expression of B7-H4 and GLUT-1 in various ovarian tissues, and the relationship between the expression of B7-H4 and GLUT-1 was analyzed. Results The expression of B7-H4 and GLUT-1 in epithelial ovarian cancer was significantly higher than that in normal ovarian tissue, ovarian benign tissue and borderline tumor (P <0.05). The positive rates of B7-H4 and GLUT-1 in poorly differentiated ovarian cancer tissues were significantly higher than those in high and moderately differentiated ovarian tissues (P <0.05). The positive rates of B7-H4 and GLUT-1 were also significantly higher in ovarian malignancies The positive rate of lymph node metastasis in ovarian malignant tumors was significantly higher than that in mucinous malignant tumors (P <0.05), while the positive rate of lymph node metastasis was higher in GLUT-1 positive patients (P <0.05) Tumor (P <0.05), and had nothing to do with lymph node metastasis and age. Conclusions The expression of B7-H4 and GLUT-1 in epithelial ovarian cancer is increased, providing a new theoretical basis for the diagnosis and treatment of ovarian cancer.